Published on:

February 28, 2023

Updated on:

Ibogaine: Mechanisms of Action

An image showing a person and a diagram of human brain.

Ibogaine is a fascinating psychoactive alkaloid with a complex pharmacological profile that has captured the attention of researchers, clinicians, and individuals seeking alternative therapies for addiction and other mental health conditions. It can be found in the long-used entheogen Iboga and other plants.

While most psychedelics work primarily by activating the serotonin receptors, ibogaine appears to have a unique set of effects on multiple neurotransmitter systems, including serotonin, dopamine, glutamate, sigma, opioid, and cholinergic pathways.

These effects are thought to contribute to the hallucinogenic and therapeutic effects of the compound, but the exact mechanisms are still not fully understood.

In this article, we will delve into the various mechanisms of action and effects of ibogaine and explore how they may contribute to its potential benefits for addiction, depression, and other mental health conditions.

Keep reading to discover the latest research on ibogaine’s impact on neurotransmitter systems and highlight the potential implications of these findings for clinical practice.

Serotonergic Effects

Serotonin is a major neurotransmitter in the brain that plays a crucial role in the brain’s function and regulation of various physiological processes. It is essential for regulating mood, sleep, appetite, cognition, pain perception, social behavior, and more!

Unlike most psychedelics, which work primarily by activating the serotonin receptors, and more specifically, 5-HT2A, ibogaine appears to be only a partial agonist (1).

This means it activates the receptor to a certain extent but not as strongly as a full agonist would. The partial agonist effect of the alkaloid is thought to contribute to its hallucinogenic effects.

The researchers also suggest that there may be an effect of ibogaine on other serotonin receptors, such as 5-HT1A and 5-HT3, but the evidence remains uncertain.

At the same time, studies clearly show that ibogaine can reversibly inhibit the reuptake of serotonin in the brain (2). Thus, ibogaine is a non-competitive serotonin reuptake inhibitor.

This results in an increased amount of the neurotransmitter in the synaptic cleft and prolongs its effect on target cells, as shown by in vivo studies (3).

The effect of blocking the serotonin transporters, also known as serotonin reuptake pumps (SERT), is similar to the mechanism of action of some antidepressant medications, such as SSRIs, which also increase serotonin levels in the brain.

However, the researchers note that ibogaine also stabilizes the SERT in an ‘inward-facing’ confirmation that is different compared to the effect of SSRIs (2).

These effects suggest that ibogaine may have complex and multifaceted serotonergic effects. In particular, the increased serotonin levels in the brain may mediate the potential antidepressant effects of ibogaine.

Indeed, several animal studies have found that acute administration of ibogaine induced a dose- and time-dependent antidepressant-like effect in rats without affecting animal locomotor activity (4).

Dopaminergic Effects

Dopamine is a neurotransmitter that plays a critical role in the brain’s function, particularly in the regulation of movement, motivation, reward, and pleasure.

Yet, studies are conflicting regarding the effects of ibogaine on dopamine signaling in the brain.

Some preclinical studies have suggested that ibogaine may enhance the release of dopamine in certain brain regions, such as the striatum, while other experiments note that the alkaloid actually lowers dopamine release (5).

Scientists suggest that these complex effects may be due to an interaction between ibogaine and the dopamine transporter (DAT) in the brain which reuptakes the neurotransmitter and lowers its concentration.

By interacting with DAT, Ibogaine appears to modify and dampen the dopamine response to addictive drugs. For example, researchers reported that the alkaloid reduced morphine-induced and nicotine-induced dopamine release (6).

In contrast, the scientists report that ibogaine enhanced the cocaine-induced increase in dopamine, while other studies report the exact opposite – dampening the dopamine increase after cocaine (7).

Studies suggest that ibogaine can upregulate the expression of DAT and ‘correct’ deficiently folded dopamine reuptake pumps (8), (9).

The alkaloid also increases the expression of neurotrophic factors such as GDNF and BDNF in the dopaminergic pathways in the brain, especially in the midbrain, which produces the majority of dopamine in the central nervous system (10).

GDNF and BDNF are neurotrophic factors in the brain that have profound importance for brain health and nerve cell survival. The upregulation of these factors and, more specifically, GDNF may also have major implications for the long-lasting anti-addictive properties of ibogaine (11).

Ibogaine may also interact with some of the dopamine receptors in the brain, but the precise nature of this interaction is not well understood.

Regardless, ibogaine has a unique effect on modulating dopamine activity and signaling, which are related to its benefits for reducing cravings and withdrawal symptoms associated with addiction.

Thus, by dampening dopamine responses to addictive drugs, modulating DAT, and upregulating GDNF levels in the brain’s dopaminergic pathways, ibogaine may exert potent and lasting anti-addictive and anti-withdrawal properties.

Effects on Opioid Receptors

Ibogaine and its metabolites have shown affinity to several opioid receptors, namely mu, kappa, and delta.

The mu-opioid receptors are the ones activated by classic opiates such as morphine, and they play a role in processes related to the perception of pain, reward mechanisms, and forming of addictions (12).

Ibogaine appears to act as an agonist to the mu-opioid receptors (13). However, other researchers report the alkaloid and its metabolites may also have partial antagonistic effects (14).

Due to its complex effects on the mu-opioid receptors, ibogaine does not exert any of the effects of classic opioids. However, it appears to re-sensitize users to the effects of opioids.

Delta receptors are also involved in pain perception and also modulate emotional reactivity (15). Ibogaine binds weakly to those receptors, but in theory, this may have benefits for mood disorders.

Kappa receptors are also involved in mood, reward, and pain perception (16). Activation can lead to feelings of unease and discomfort, problems with coordination, and hallucinogenic effects.

Ibogaine is a reversible agonist to the kappa opioid receptors, and studies suggest that this agonism may play a role in the alkaloid’s putative anti-addictive effects (17), (18). Ultimately, the benefits of ibogaine regarding its affinity to the opioid receptors may be for mood, reduced symptoms of withdrawal, re-sensitization, and anti-addiction.

Cholinergic Effects

The cholinergic receptors are two main subtypes, nicotinic and muscarinic. Ibogaine interacts with both subtypes of receptors and appears to be a relatively potent inhibitor (19).

Most notably, studies suggest that ibogaine and its metabolites may block the α3β4 receptors, which are a type of nicotinic acetylcholine receptor (nAChR) (20).

These receptors are particularly abundant in the mesolimbic dopamine system, which is involved in reward, motivation, and addiction. They are activated by the neurotransmitter acetylcholine but also by nicotine and other compounds.

In fact, the α3β4 receptor subtype has been of particular interest in addiction research, as it is believed to play a key role in the reinforcing effects of nicotine and other addictive substances.

Recent research suggests that the inhibition of α3β4 nicotinic acetylcholine receptors (nAChRs) represents another probable mechanism of action for ibogaine’s potent anti-addictive properties (21).

It’s also important to note that the blockade of ibogaine to the nicotinic receptors is not completely reversible, which indicates long-term effectiveness.

Effects on Glutamate Receptors

Glutamate is the primary excitatory neurotransmitter in the brain, and its activity is important for a wide range of physiological processes, including learning and memory, neural development, and synaptic plasticity (22).

However, excessive glutamate release can lead to excitotoxicity and contribute to neuronal damage in conditions such as stroke and traumatic brain injury. Glutamate receptors can be AMPA, NMDA, and Kainate receptors.

Ibogaine appears to interact primarily with NMDA receptors, although the exact mechanisms through which it does so are not fully understood. Studies suggest that it blocks them by working as a competitive antagonist for the NMDA receptors (23).

Furthermore, studies show that by inhibiting NMDA receptors, ibogaine exerts long-term protective effects in experimental models against NMDA-induced seizures (24).

According to the researchers, this may also be related to its long-lasting anti-addictive properties (25). One of the mechanisms is related to the fact that by antagonizing the NMDA receptors, ibogaine also inhibits the NMDA-evoked release of dopamine.

Ultimately, the researchers suggest that by interacting with the NMDA receptors, ibogaine can help “rewire” the brain and promote long-term anti-addictive effects.

Effects on Sigma Receptors

The σ (sigma) 1 and σ 2 receptors are intracellular, mitochondrial membrane chaperone proteins that act as signal transduction amplifiers in the brain and modulate the release and uptake of neurotransmitters.

Ibogaine has a high affinity for sigma-2 receptors, which are found primarily in the peripheral and central nervous systems, and a much lower affinity for sigma-1.

The effects of ibogaine on sigma-2 receptors are unique, but the exact mechanisms through which it interacts with these receptors are still not fully understood.

Research suggests that this interaction may play a role in ibogaine’s anti-addictive effects. That’s because ibogaine’s interaction with sigma-2 receptors may modulate dopamine release in the brain, which could explain its complex effects on dopamine levels (25).

Other ibogaine-related alkaloids also activate the sigma-2 receptors in the brain, which is thought to mediate several benefits for the brain, such as antidepressant effects (26).

In addition, ibogaine has been shown to have neuroprotective effects in certain cell and animal models through its interaction with sigma-1 receptors. More specifically, the alkaloid may have the potential to attenuate autoinflammation in neural tissues (27).

Ultimately, the effect of ibogaine on the sigma receptors may be a major factor in mediating its anti-addictive, antidepressant, and neuroprotective properties.

References:

Repke DB, Artis DR, Nelson JT, Wong EHF. Abbreviated Ibogaine Congeners. Synthesis and Reactions of Tropan-3-yl-2- and -3-indoles. Investigation of an Unusual Isomerization of 2-Substituted Indoles Using Computational and Spectroscopic Techniques. The Journal of Organic Chemistry. 1994;59(8):2164-2171. doi:https://doi.org/10.1021/jo00087a037
Bulling S, Schicker K, Zhang YW, et al. The mechanistic basis for non-competitive ibogaine inhibition of serotonin and dopamine transporters. J Biol Chem. 2012;287(22):18524-18534. doi:10.1074/jbc.M112.343681
Benwell ME, Holtom PE, Moran RJ, Balfour DJ. Neurochemical and behavioural interactions between ibogaine and nicotine in the rat. Br J Pharmacol. 1996;117(4):743-749. doi:10.1111/j.1476-5381.1996.tb15253.x
Rodrı Guez P, Urbanavicius J, Prieto JP, et al. A Single Administration of the Atypical Psychedelic Ibogaine or Its Metabolite Noribogaine Induces an Antidepressant-Like Effect in Rats. ACS Chem Neurosci. 2020;11(11):1661-1672. doi:10.1021/acschemneuro.0c00152
Maisonneuve IM, Rossman KL, Keller RW Jr, Glick SD. Acute and prolonged effects of ibogaine on brain dopamine metabolism and morphine-induced locomotor activity in rats. Brain Res. 1992;575(1):69-73. doi:10.1016/0006-8993(92)90424-8
Glick SD, Maisonneuve IM. Development of novel medications for drug addiction. The legacy of an African shrub. Ann N Y Acad Sci. 2000;909:88-103. doi:10.1111/j.1749-6632.2000.tb06677.x
Broderick PA, Phelan FT, Eng F, Wechsler RT. Ibogaine modulates cocaine responses which are altered due to environmental habituation: in vivo microvoltammetric and behavioral studies. Pharmacol Biochem Behav. 1994;49(3):711-728. doi:10.1016/0091-3057(94)90092-2
Beerepoot P, Lam VM, Salahpour A. Pharmacological Chaperones of the Dopamine Transporter Rescue Dopamine Transporter Deficiency Syndrome Mutations in Heterologous Cells. J Biol Chem. 2016;291(42):22053-22062. doi:10.1074/jbc.M116.749119
Bhat S, Guthrie DA, Kasture A, et al. Tropane-Based Ibogaine Analog Rescues Folding-Deficient Serotonin and Dopamine Transporters. ACS Pharmacol Transl Sci. 2020;4(2):503-516. Published 2020 Aug 28. doi:10.1021/acsptsci.0c00102
Marton S, González B, Rodríguez-Bottero S, et al. Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits. Front Pharmacol. 2019;10:193. Published 2019 Mar 5. doi:10.3389/fphar.2019.00193
He DY, Ron D. Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, ibogaine. FASEB J. 2006;20(13):2420-2422. doi:10.1096/fj.06-6394fje
Pasternak GW, Pan YX. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev. 2013;65(4):1257-1317. Published 2013 Sep 27. doi:10.1124/pr.112.007138
Codd EE. High affinity ibogaine binding to a mu opioid agonist site. Life Sci. 1995;57(20):PL315-PL320. doi:10.1016/0024-3205(95)02171-e
Antonio T, Childers SR, Rothman RB, et al. Effect of Iboga alkaloids on µ-opioid receptor-coupled G protein activation. PLoS One. 2013;8(10):e77262. Published 2013 Oct 16. doi:10.1371/journal.pone.0077262
Chu Sin Chung P, Kieffer BL. Delta opioid receptors in brain function and diseases. Pharmacol Ther. 2013;140(1):112-120. doi:10.1016/j.pharmthera.2013.06.003
Cahill CM, Taylor AM, Cook C, Ong E, Morón JA, Evans CJ. Does the kappa opioid receptor system contribute to pain aversion?. Front Pharmacol. 2014;5:253. Published 2014 Nov 17. doi:10.3389/fphar.2014.00253
Glick SD, Maisonneuve IM, Pearl SM. Evidence for roles of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine. Brain Res. 1997;749(2):340-343. doi:10.1016/S0006-8993(96)01414-X
Sershen H, Hashim A, Lajtha A. The effect of ibogaine on kappa-opioid- and 5-HT3-induced changes in stimulation-evoked dopamine release in vitro from striatum of C57BL/6By mice. Brain Res Bull. 1995;36(6):587-591. doi:10.1016/0361-9230(94)00250-5
Sweetnam PM, Lancaster J, Snowman A, et al. receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine’s putative anti-addictive activity. Psychopharmacology (Berl). 1995;118(4):369-376. doi:10.1007/BF02245936
Arias HR, Rosenberg A, Targowska-Duda KM, et al. interaction of ibogaine with human alpha3beta4-nicotinic acetylcholine receptors in different conformational states. Int J Biochem Cell Biol. 2010;42(9):1525-1535. doi:10.1016/j.biocel.2010.05.011
Straub CJ, Rusali LE, Kremiller KM, Riley AP. What We Have Gained from Ibogaine: α3β4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders. J Med Chem. 2023;66(1):107-121. doi:10.1021/acs.jmedchem.2c01562
Kennedy MB. Synaptic Signaling in Learning and Memory. Cold Spring Harb Perspect Biol. 2013;8(2):a016824. Published 2013 Dec 30. doi:10.1101/cshperspect.a016824
Glick SD, Maisonneuve IS. Mechanisms of anti-addictive actions of ibogaine. Ann N Y Acad Sci. 1998;844:214-226.
Leal MB, de Souza DO, Elisabetsky E. Long-lasting ibogaine protection against NMDA-induced convulsions in mice. Neurochem Res. 2000;25(8):1083-1087. doi:10.1023/a:1007665911622
Sershen H, Hashim A, Lajtha A. The effect of ibogaine on sigma- and NMDA-receptor-mediated release of [3H]dopamine. Brain Res Bull. 1996;40(1):63-67. doi:10.1016/0361-9230(96)00039-1
Popik P, Skolnick P. Chapter 3 – Pharmacology of Ibogaine and Ibogaine-Related Alkaloids. The Alkaloids: Chemistry and Biology. Published online 1999. Accessed February 27, 2023. https://www.semanticscholar.org/paper/Chapter-3-Pharmacology-of-Ibogaine-and-Alkaloids-Popik-Skolnick/25bc05445f838584cc77536469533ef2f2f5f6fb
Thompson C, Szabo A. Psychedelics as a novel approach to treating autoimmune conditions. Immunol Lett. 2020;228:45-54. doi:10.1016/j.imlet.2020.10.001

FAQ's

Ayahuasca vs. Iboga or Ibogaine

Which is stronger, Iboga or Ayahuasca?

Both are powerful master plants, but they work in fundamentally different ways. Iboga produces a deeper, longer, more singular experience — a single ceremony unfolds over the course of a day and delivers insights that integrate for years. Ayahuasca offers shorter, cyclical journeys (4–6 hours) that most participants repeat many times over a lifetime. Strength depends on what you're seeking: Iboga's depth and durability, or Ayahuasca's ongoing visionary dialogue.

‍

Should I do Iboga or Ayahuasca First?

There is no universal answer, but the two medicines tend to serve different purposes. Ayahuasca is typically worked with over many ceremonies as an ongoing path of exploration and teaching. Iboga, by contrast, is generally a complete healing in itself — most people do not need further plant medicine work for healing afterward, and any continued ceremony tends to be for exploration rather than resolution. If you are seeking lasting resolution to a specific pattern such as addiction, trauma, or behavioral compulsion, Iboga is generally the more direct path.

‍

Which is more effective for addiction — Iboga or Ayahuasca?

Clinical research points to ibogaine as the most-studied direct intervention for substance use. In one of the largest trials, 30% of 88 participants completely eliminated their addiction after ibogaine therapy and 54% remained abstinent for more than a year. Ayahuasca shows anti-addictive properties in research but typically requires sustained, repeated ceremony work.

Importantly, research has also documented anti-addictive activity in the other principal Iboga alkaloids — coronaridine, ibogamine, and voacangine — which together with ibogaine are referred to in the research literature as the "CIVI-complex." At Root Healing, our experience confirms what the Bwiti have held for thousands of years: whole-plant Iboga is the most effective path, because its full spectrum of alkaloids works synergistically. This is why our work is rooted in Iboga itself, supported by ibogaine-grade safety protocols and boutique, lineage-led care.

‍

Is Iboga safer than Ayahuasca?

Each has its own risk profile. Ayahuasca is generally well tolerated but interacts dangerously with SSRIs, certain medications, and tyramine-rich foods. Iboga requires more rigorous medical screening — particularly cardiac and liver function — because it can prolong the QT interval. With proper screening and medical oversight, Iboga is very safe. At Root Healing, we hold ibogaine-grade safety protocols, including continuous EKG monitoring throughout ceremony, alongside our boutique, lineage-led care.

How long does an Iboga ceremony last compared to an Ayahuasca ceremony?

An Ayahuasca ceremony typically lasts 4–6 hours. An Iboga ceremony is significantly longer, generally unfolding over the course of a day, with an extended visionary phase followed by a long reflective integration period. The duration of healing also differs: Ayahuasca's benefits generally last 1–2 months and are reinforced through repeated ceremonies, while Iboga's effects often last from many months to a lifetime, with most people completing their core work in 1–3 ceremonies.

Why does Ayahuasca require so many more ceremonies than Iboga?

Ayahuasca teaches through symbolic, visionary experience that takes time to decipher and can fade with daily life, which is why ongoing ceremony is part of the tradition. Iboga delivers direct, unambiguous insight into a person's patterns, behaviors, and relationship with self. Because these realizations are concrete rather than symbolic, they integrate more durably, and most people complete their foundational work in 1–3 ceremonies.

How do I know whether Iboga is the right medicine for me?

Iboga tends to call those ready for direct, grounded clarity — people seeking lasting resolution rather than open-ended exploration. It is often chosen for substance use, behavioral addiction, trauma, neurological conditions, or a felt disconnection from self and life. Those drawn primarily to visionary, symbolic experience may resonate more with Ayahuasca, and we hold deep respect for that path. For those seeking a complete, lasting healing rooted in an ancient tradition and supported by modern research, Iboga is uniquely suited. Our application and medical screening process at Root Healing help us assess alignment together.

Where are Iboga and Ayahuasca legal?

Ayahuasca is legal in Brazil, Peru, Ecuador, and Costa Rica, and is permitted in the United States only within specific religious exemptions. Iboga and ibogaine are legal in Mexico, Costa Rica, Brazil, South Africa, Gabon, New Zealand, and the Netherlands, among others. In the United States, ibogaine is federally Schedule I, though sacramental Iboga ceremonies are protected within recognized religious traditions. Root Healing operates retreats in Mexico (our flagship center in Tepoztlán), the United States (through the Missoko Bwiti Alliance, our 501(c)(3) church entity in Oregon), and Europe — each within the appropriate legal and traditional framework.

What are the cultural and spiritual origins of Iboga and Ayahuasca?

Iboga is the sacrament of the Bwiti tradition of West-Central Africa, centered in Gabon, Cameroon, and the Democratic Republic of the Congo. Bwiti is one of the oldest continuous spiritual lineages on earth, and Iboga is regarded as the master plant that initiates a person into truth, ancestry, and self. Ayahuasca originates with indigenous tribes of the Upper Amazon Basin — Peru, Brazil, Colombia, and Ecuador — where shamans, or ayahuasqueros, prepare it ceremonially with icaros (sacred songs) and visionary work. Both are profound traditions; Root Healing's work is rooted specifically in the Missoko Bwiti lineage, in direct relationship with our Bwiti elders.

‍

Do Iboga and Ayahuasca cause purging?

Both can, but in different ways. Ayahuasca is well known for la purga — vomiting, diarrhea, sweating, and emotional release that is traditionally understood as the medicine clearing what no longer belongs. Iboga can also produce nausea or vomiting, particularly as the body releases stored substances or trauma, though this is generally less central to the experience than with Ayahuasca. With Iboga, the deeper "purge" is psychological and emotional — a clarifying release of patterns, dishonesty, and dissonance with the self. At Root Healing, our medical team and traditional facilitators support participants throughout to ensure both safety and ease.

Can Iboga and Ayahuasca help with depression and anxiety?

Both have shown therapeutic potential, but Iboga offers a more comprehensive path for depression and anxiety. Pharmacologically, Iboga works on a broader range of neurotransmitter systems than Ayahuasca — modulating dopamine, serotonin, and acetylcholine, while activating sigma-1 receptors and upregulating key neurotrophic growth factors including GDNF and BDNF. This combination supports mood regulation, nervous-system resilience, and long-term neuroplasticity in ways that Ayahuasca's primarily serotonergic (DMT-driven) mechanism does not fully reach. Clinical research reflects this depth: studies have reported significant reductions in depression after ibogaine treatment, and one PTSD trial documented relief from anxiety, cognitive impairment, and suicidal ideation in all 51 participants.

Equally important is what comes alongside the medicine. The Missoko Bwiti tradition that holds Iboga is itself a complete framework for working with depression, anxiety, and emotional disconnection — offering ceremony, ancestral connection, and a way of relating to the self that integrates the insights of the medicine into daily life long after retreat. At Root Healing, this lineage-led care is woven through every stage of the journey, from preparation through retreat to post-retreat integration, which is where lasting healing for depression and anxiety is most often built.

Can you microdose Iboga or Ayahuasca?

Microdosing Iboga is a recognized practice within the Bwiti tradition and in modern wellness contexts, where small daily or periodic doses of root bark are used to support clarity, focus, mood, and gentle neuroregenerative effects. Ayahuasca is generally not microdosed in the same way, as its effects depend on the synergy between DMT and the MAOI in the brew, which becomes complicated at sub-perceptual doses; some practitioners microdose the Banisteriopsis caapi vine alone for its mood and nervous-system benefits. At Root Healing, microdosing is approached with the same care as full ceremony — aligned with tradition, supported by science, and never a substitute for full healing work when that is what is called for.